Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD1775 with Docetaxel and Cisplatin in HNSCC
NCT02508246Phase 1Completed
- Sponsor
- University of Washington
- Start
- Jul 2015
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adavosertib in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Washington. Primary endpoints: Incidence of adverse events and Maximum Tolerated Dose at 28 days. Started Jul 2015; status: completed.
02
Drugs
adavosertib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT02508246.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02508246.